STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. (Q34124346)

31 July 2017

1 reference

title

STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. (English)

1 reference

31 July 2017

1

Blagosklonny MV

1 reference

31 July 2017

publication date

1 April 2002

1 reference

31 July 2017

1 reference

31 July 2017

volume

16

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

570-572

1 reference

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

Cancer research. Why some leukemia cells resist STI-571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

New-age drug meets resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

How carcinogens (or telomere dysfunction) induce genetic instability: associated-selection model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

Genetic instabilities in human cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402409

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402409

1 reference

Dimensions Publication ID

31 July 2017

1011732524

0 references

1 reference